# PERCEIVE-I (multi-omic blood test for gynaecological cancers)

Source: https://onco.cc/trials/perceive-1/  
OnCo record `perceive-1` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Chinese study developing a blood test for several gynaecological cancers at once.

## Summary

PERCEIVE-I (NCT04903665) is an observational study sponsored by Fudan University with Guangzhou Burning Rock Bioengineering Ltd. It develops and validates combined cell-free DNA methylation, mutation and microRNA assays for early detection of gynaecological cancers.

The registry record, read on 29 October 2026, gives its status as unknown (the sponsor last updated it on 28 July 2022), with 495 participants enrolled, a start on 11 February 2021 and primary completion expected on 22 August 2022.

## Fields

- Kind: Trial
- Last checked: 2026-10-29
- Also known as: PERCEIVE-I
- Registry id: NCT04903665
- Phase: observational
- Setting: Women with gynaecological cancers or benign disease at Fudan University, testing methylation, mutation and microRNA markers in blood
- Sponsor: Fudan University with Guangzhou Burning Rock Bioengineering Ltd.
- Enrolled: 495

## Sources

- ClinicalTrials.gov NCT04903665: https://clinicaltrials.gov/study/NCT04903665

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- companies: [Burning Rock Biotech](https://onco.cc/companies/burning-rock/)
- trials: [PERCEIVE-II (extended validation for gynaecological cancers)](https://onco.cc/trials/perceive-2/)

---
JSON: https://onco.cc/api/v1/entities/perceive-1.json